ARDSLEY, NY (December 27, 2018) — The U.S. Food and Drug Administration (FDA) has approved INBRIJA™, a levodopa inhalation powder developed by Acorda Therapeutics, as a treatment for “off” periods in people with Parkinson’s disease (PD) who are treated with carbidopa/levodopa.
Quick Facts about INBRIJA™:
- INBRIJA™ is the first and only FDA-approved inhaled levodopa for intermittent treatment of “off” periods in people with PD taking carbidopa/levodopa.
- This new treatment is expected to be available in the first quarter of 2019.
For more information about INBRIJA™ and other PD treatments, contact the Parkinson’s Foundation Helpline at 1-800-4PD-INFO (473-4636) or Helpline@Parkinson.org. You can also read more about INBRIJA™ in this press release from Acorda Therapeutics.
More information about ways to manage “off” time can be found in our podcast episode How to Manage Parkinson’s “Off” Time.
About the Parkinson’s Foundation
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson’s Foundation has invested more than $400 million in Parkinson’s research and clinical care. Connect with us on Parkinson.org, Facebook, Twitter, Instagram or call (800) 4PD-INFO (473-4636).
About Parkinson’s Disease
Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the U.S. alone.